Investment
Features
FeesSafety
Academy
More
Pluang+

TRON plans to launch tokenized stocks and Treasuries by Q4 2026, expanding beyond digital dollars.

Protocol Fundamentals
19 Oct 2026
Crypto Briefing
View Source
Bullish
TRON plans to launch tokenized stocks and Treasuries by Q4 2026, expanding beyond digital dollars.

TRON founder Justin Sun announced plans to introduce tokenized stocks and US Treasuries on the TRON network by Q4 2026, aiming to expand beyond its current role in digital dollars. This move targets global users, especially in Asia and emerging markets, seeking US asset exposure via blockchain rather than traditional brokers. Sun projects the tokenized stock market could exceed $100 billion within five years and will proceed using existing regulatory frameworks without waiting for new Congressional legislation. Additionally, TRON is developing AI agents for autonomous transactions and plans to implement post-quantum security upgrades by the end of 2026.

Justin Sun's TRON network plans to expand into tokenized stocks and US Treasuries by Q4 2026. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Oct 20, 2026 03:42 WIB: out of 50 major cryptocurrencies, 46 rose and 3 fell today. Notable movers include CRV at Rp6.517 with a 9.94% increase and a typical hold time of 62 days, DOT at Rp20.418 up 8.37% with a 121-day hold time, and EOS at Rp12.649 rising 8.13% with an 87-day hold time.

More News

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
1 hour ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
1 hour ago
Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...

Company Fundamentals
Bullish
2 hours ago
Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...

Market News
Neutral
3 hours ago
W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...

Company Fundamentals
Neutral
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App